Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for genetic manipulation. In this review, we discuss the current development of CRISPR/Cas9 technologies for therapeutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. The potential of genetic manipulation using CRISPR/Cas9 system to generate universal CAR T cells and potent T cells that are resistant to exhaustion and inhibition is explored. We also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy. As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Given the tremendous progress that has been made in the past few years, we believe that the CRISPR/Cas9 technology holds immense promise for advancing immunotherapy.

Keywords

CRISPR/Cas9 / chimeric antigen receptor / T lymphocytes / adoptive immunotherapy / gene therapy

References

[1] AuerTO, DuroureK, De CianA, ConcordetJP, Del BeneF (2014) Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res24:142–153

[2] BarrangouR, FremauxC, DeveauH, RichardsM, BoyavalP, MoineauS, RomeroDA, HorvathP (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science315:1709–1712

[3] BibikovaM, GolicM, GolicKG, CarrollD (2002) Targeted chromosomal cleavage and mutagenesis in Drosophilausing zinc-finger nucleases. Genetics161:1169–1175

[4] BibikovaM, BeumerK, TrautmanJK, CarrollD (2003) Enhancing gene targeting with designed zinc finger nucleases. Science300:764

[5] BochJ, ScholzeH, SchornackS, LandgrafA, HahnS, KayS, LahayeT, NickstadtA, BonasU (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science326:1509–1512

[6] BrentjensRJ, LatoucheJB, SantosE, MartiF, GongMC, LyddaneC, KingPD, LarsonS, WeissM, RiviereI (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med9:279–286

[7] BriggsAW, RiosX, ChariR, YangL, ZhangF, MaliP, ChurchGM (2012) Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res40:e117

[8] CarpenitoC, MiloneMC, HassanR, SimonetJC, LakhalM, SuhoskiMM, Varela-RohenaA, HainesKM, HeitjanDF, AlbeldaSM (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA106:3360–3365

[9] CermakT, DoyleEL, ChristianM, WangL, ZhangY, SchmidtC, BallerJA, SomiaNV, BogdanoveAJ, VoytasDF (2011) Efficient design and assembly of custom TALEN and other TAL effectorbased constructs for DNA targeting. Nucleic Acids Res39:e82

[10] ChavezA, ScheimanJ, VoraS, PruittBW, TuttleM, IyerPRE, LinS, KianiS, GuzmanCD, WiegandDJ (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods12:326–328

[11] ChengAW, WangH, YangH, ShiL, KatzY, TheunissenTW, RangarajanS, ShivalilaCS, DadonDB, JaenischR (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res23:1163–1171

[12] ChiS, WeissA, WangH (2016) A CRISPR-based toolbox for studying Tcell signal transduction. Biomed Res Int2016:5052369

[13] ChoSW, KimS, KimY, KweonJ, KimHS, BaeS, KimJS (2014) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res24:132–141

[14] CongL, RanFA, CoxD, LinS, BarrettoR, HabibN, HsuPD, WuX, JiangW, MarraffiniLA (2013) Multiplex genome engineering using CRISPR/Cas systems. Science339:819–823

[15] CrosettoN, MitraA, SilvaMJ, BienkoM, DojerN, WangQ, KaracaE, ChiarleR, SkrzypczakM, GinalskiK (2013) Nucleotideresolution DNA double-strand break mapping by next-generation sequencing. Nat Methods10:361–365

[16] CyranoskiD (2016) CRISPR gene-editing tested in a person for the first time. Nature539:479

[17] DeltchevaE, ChylinskiK, SharmaCM, GonzalesK, ChaoY, PirzadaZA, EckertMR, VogelJ, CharpentierE (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature471:602–607

[18] DiCarloJE, NorvilleJE, MaliP, RiosX, AachJ, ChurchGM (2013) Genome engineering in Saccharomyces cerevisiaeusing CRISPR-Cas systems. Nucleic Acids Res41:4336–4343

[19] DoyonY, McCammonJM, MillerJC, FarajiF, NgoC, KatibahGE, AmoraR, HockingTD, ZhangL, RebarEJ (2008) Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol26:702–708

[20] EyquemJ, Mansilla-SotoJ, GiavridisT, van der StegenSJ, HamiehM, CunananKM, OdakA, GonenM, SadelainM (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature543:113–117

[21] FriedlandAE, BaralR, SinghalP, LoveluckK, ShenS, SanchezM, MarcoE, GottaGM, MaederML, KennedyEM (2015) Characterization of Staphylococcus aureusCas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol16:257

[22] FrockRL, HuJ, MeyersRM, HoYJ, KiiE, AltFW (2015) Genomewide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol33:179–186

[23] FuY, FodenJA, KhayterC, MaederML, ReyonD, JoungJK, SanderJD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol31:822–826

[24] FuY, SanderJD, ReyonD, CascioVM, JoungJK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol32:279–284

[25] GasiunasG, BarrangouR, HorvathP, SiksnysV (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA109: E2579–2586

[26] GilbertLA, LarsonMH, MorsutL, LiuZ, BrarGA, TorresSE, Stern-GinossarN, BrandmanO, WhiteheadEH, DoudnaJA (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell154:442–451

[27] GonzalezF, ZhuZ, ShiZD, LelliK, VermaN, LiQV, HuangfuD (2014) An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell15:215–226

[28] GrossG, WaksT, EshharZ (1989) Expression of immunoglobulin-Tcell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA86:10024–10028

[29] GuilingerJP, ThompsonDB, LiuDR (2014) Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol32:577–582

[30] HeX, TanC, WangF, WangY, ZhouR, CuiD, YouW, ZhaoH, RenJ, FengB (2016) Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res44:e85

[31] HendelA, BakRO, ClarkJT, KennedyAB, RyanDE, RoyS, SteinfeldI, LunstadBD, KaiserRJ, WilkensAB (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol33:985–989

[32] HiltonIB, D’IppolitoAM, VockleyCM, ThakorePI, CrawfordGE, ReddyTE, GersbachCA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol33:510–517

[33] HoosA (2016) Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov15:235–247

[34] HorvathP, BarrangouR (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science327:167–170

[35] HouP, ChenS, WangS, YuX, ChenY, JiangM, ZhuangK, HoW, HouW, HuangJ (2015) Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep5:15577

[36] HsuPD, ScottDA, WeinsteinJA, RanFA, KonermannS, AgarwalaV, LiY, FineEJ, WuX, ShalemO (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol31:827–832

[37] HuW, KaminskiR, YangF, ZhangY, CosentinoL, LiF, LuoB, Alvarez-CarbonellD, Garcia-MesaY, KarnJ (2014) RNAdirected gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA111:11461–11466

[38] HwangWY, FuY, ReyonD, MaederML, TsaiSQ, SanderJD, PetersonRT, YehJR, JoungJK (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol31:227–229

[39] IrvingBA, WeissA (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell64:891–901

[40] JinekM, ChylinskiK, FonfaraI, HauerM, DoudnaJA, CharpentierE (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science337:816–821

[41] KalosM, JuneCH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity39:49–60

[42] KearnsNA, PhamH, TabakB, GengaRM, SilversteinNJ, GarberM, MaehrR (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods12:401–403

[43] KimHJ, LeeHJ, KimH, ChoSW, KimJS (2009) Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res19:1279–1288

[44] KimS, KimD, ChoSW, KimJ, KimJS (2014) Highly efficient RNAguided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res24:1012–1019

[45] KimD, BaeS, ParkJ, KimE, KimS, YuHR, HwangJ, KimJI, KimJS (2015). Digenome-seq: genome-wide profiling of CRISPRCas9 off-target effects in human cells. Nat Methods12:237–243, 231–243

[46] KonermannS, BrighamMD, TrevinoAE, JoungJ, AbudayyehOO, BarcenaC, HsuPD, HabibN, GootenbergJS, NishimasuH (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature517:583–588

[47] LiJF, NorvilleJE, AachJ, McCormackM, ZhangD, BushJ, ChurchGM, SheenJ (2013) Multiplex and homologous recombinationmediated genome editing in Arabidopsis and Nicotiana benthamianausing guide RNA and Cas9. Nat Biotechnol31:688–691

[48] LiC, GuanX, DuT, JinW, WuB, LiuY, WangP, HuB, GriffinGE, ShattockRJ (2015) Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirusdelivered CRISPR/Cas9. J Gen Virol96:2381–2393

[49] LiuX, ZhangY, ChengC, ChengAW, ZhangX, LiN, XiaC, WeiX, LiuX, WangH (2017) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res27:154–157

[50] LloydA, VickeryON, LaugelB (2013) Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol4:221

[51] LongC, McAnallyJR, SheltonJM, MireaultAA, Bassel-DubyR, OlsonEN (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science345:1184–1188

[52] MaederML, LinderSJ, CascioVM, FuY, HoQH, JoungJK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods10:977–979

[53] MaherJ, BrentjensRJ, GunsetG, RiviereI, SadelainM(2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol20:70–75

[54] MakarovaKS, GrishinNV, ShabalinaSA, WolfYI, KooninEV (2006) A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct1:7

[55] MaliP, AachJ, StrangesPB, EsveltKM, MoosburnerM, KosuriS, YangL, ChurchGM (2013a) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol31:833–838

[56] MaliP, YangL, EsveltKM, AachJ, GuellM, DiCarloJE, NorvilleJE, ChurchGM (2013b) RNA-guided human genome engineering via Cas9. Science339:823–826

[57] MandalPK, FerreiraLM, CollinsR, MeissnerTB, BoutwellCL, FriesenM, VrbanacV, GarrisonBS, StortchevoiA, BryderD (2014) Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell15:643–652

[58] MausMV, GruppSA, PorterDL, JuneCH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood123:2625–2635

[59] MillerJC, TanS, QiaoG, BarlowKA, WangJ, XiaDF, MengX, PaschonDE, LeungE, HinkleySJ (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol29:143–148

[60] MortonJ, DavisMW, JorgensenEM, CarrollD (2006) Induction and repair of zinc-finger nuclease-targeted double-strand breaks in Caenorhabditis elegans somatic cells. Proc Natl Acad Sci USA103:16370–16375

[61] MoscouMJ, BogdanoveAJ (2009) A simple cipher governs DNA recognition by TAL effectors. Science326:1501

[62] NakadeS, TsubotaT, SakaneY, KumeS, SakamotoN, ObaraM, DaimonT, SezutsuH, YamamotoT, SakumaT (2014)Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat Commun5:5560

[63] NekrasovV, StaskawiczB, WeigelD, JonesJD, KamounS (2013) Targeted mutagenesis in the model plant Nicotiana benthamianausing Cas9 RNA-guided endonuclease. Nat Biotechnol31:691–693

[64] PavletichNP, PaboCO (1991) Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science252:809–817

[65] PerezEE, WangJ, MillerJC, JouvenotY, KimKA, LiuO, WangN, LeeG, BartsevichVV, LeeYL (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol26:808–816

[66] Perez-PineraP, KocakDD, VockleyCM, AdlerAF, KabadiAM, PolsteinLR, ThakorePI, GlassKA, OusteroutDG, LeongKW (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods10:973–976

[67] PoirotL, PhilipB, Schiffer-ManniouiC, Le ClerreD, Chion-SotinelI, DerniameS, PotrelP, BasC, LemaireL, GalettoR (2015) Multiplex genome-edited T-cell manufacturing platform for “Offthe-Shelf” adoptive T-cell immunotherapies. Cancer Res75:3853–3864

[68] PorteusMH, BaltimoreD (2003) Chimeric nucleases stimulate gene targeting in human cells. Science300:763

[69] ProvasiE, GenoveseP, LombardoA, MagnaniZ, LiuPQ, ReikA, ChuV, PaschonDE, ZhangL, KuballJ (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med18:807–815

[70] QiLS, LarsonMH, GilbertLA, DoudnaJA, WeissmanJS, ArkinAP, LimWA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell152:1173–1183

[71] RanFA, HsuPD, LinCY, GootenbergJS, KonermannS, TrevinoAE, ScottDA, InoueA, MatobaS, ZhangY (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell154:1380–1389

[72] RanFA, CongL, YanWX, ScottDA, GootenbergJS, KrizAJ, ZetscheB, ShalemO, WuX, MakarovaKS (2015) In vivo genome editing using Staphylococcus aureusCas9. Nature520:186–191

[73] RenJ, LiuX, FangC, JiangS, JuneCH, ZhaoY (2016) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res16:1300

[74] RenJ, ZhangX, LiuX, FangC, JiangS, JuneCH, ZhaoY (2017) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget8:17002–17011

[75] SadelainM, PapapetrouEP, BushmanFD (2011) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer12:51–58

[76] SakumaT, TakenagaM, KawabeY, NakamuraT, KamihiraM, YamamotoT (2015) Homologous recombination-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids. Int J Mol Sci16:23849–23866

[77] SatherBD, Romano IbarraGS, SommerK, CuringaG, HaleM, KhanIF, SinghS, SongY, GwiazdaK, SahniJ (2015) Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med7:307ra156

[78] SchumannK, LinS, BoyerE, SimeonovDR, SubramaniamM, GateRE, HaliburtonGE, YeCJ, BluestoneJA, DoudnaJA (2015) Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA112:10437–10442

[79] SchwankG, KooBK, SasselliV, DekkersJF, HeoI, DemircanT, SasakiN, BoymansS, CuppenE, van der EntCK (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell13:653–658

[80] ShalemO, SanjanaNE, HartenianE, ShiX, ScottDA, MikkelsenTS, HecklD, EbertBL, RootDE, DoenchJG (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science343:84–87

[81] ShenB, ZhangJ, WuH, WangJ, MaK, LiZ, ZhangX, ZhangP, HuangX (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res23:720–723

[82] SlaymakerIM, GaoL, ZetscheB, ScottDA, YanWX, ZhangF (2016) Rationally engineered Cas9 nucleases with improved specificity. Science351:84–88

[83] SuS, HuB, ShaoJ, ShenB, DuJ, DuY, ZhouJ, YuL, ZhangL, ChenF (2016) CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep6:20070

[84] SuzukiK, TsunekawaY, Hernandez-BenitezR, WuJ, ZhuJ, KimEJ, HatanakaF, YamamotoM, AraokaT, LiZ (2016) In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature540:144–149

[85] SwiechL, HeidenreichM, BanerjeeA, HabibN, LiY, TrombettaJ, SurM, ZhangF (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol33:102–106

[86] TanenbaumME, GilbertLA, QiLS, WeissmanJS, ValeRD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell159:635–646

[87] TebasP, SteinD, TangWW, FrankI, WangSQ, LeeG, SprattSK, SuroskyRT, GiedlinMA, NicholG (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med370:901–910

[88] TorikaiH, ReikA, LiuPQ, ZhouY, ZhangL, MaitiS, HulsH, MillerJC, KebriaeiP, RabinovichB (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood119:5697–5705

[89] TownsendJA, WrightDA, WinfreyRJ, FuF, MaederML, JoungJK, VoytasDF (2009) High-frequency modification of plant genes using engineered zinc-finger nucleases. Nature459:442–445

[90] TsaiSQ, ZhengZ, NguyenNT, LiebersM, TopkarVV, ThaparV, WyvekensN, KhayterC, IafrateAJ, LeLP (2015) GUIDEseq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol33:187–197

[91] UrnovFD, MillerJC, LeeYL, BeausejourCM, RockJM, AugustusS, JamiesonAC, PorteusMH, GregoryPD, HolmesMC (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature435:646–651

[92] WangH, YangH, ShivalilaCS, DawlatyMM, ChengAW, ZhangF, JaenischR (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell153:910–918

[93] WangW, YeC, LiuJ, ZhangD, KimataJT, ZhouP (2014) CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE9:e115987

[94] WiedenheftB, SternbergSH, DoudnaJA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature482:331–338

[95] WilliamsMR, Fricano-KuglerCJ, GetzSA, SkeltonPD, LeeJ, RizzutoCP, GellerJS, LiM, LuikartBW (2016) A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons. Sci Rep6:25611

[96] WyvekensN, TopkarVV, KhayterC, JoungJK, TsaiSQ (2015) Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing. Hum Gene Ther26:425–431

[97] YeL, WangJ, BeyerAI, TequeF, CradickTJ, QiZ, ChangJC, BaoG, MuenchMO, YuJ(2014) Seamless modification of wildtype induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA111:9591–9596

[98] YinH, XueW, ChenS, BogoradRL, BenedettiE, GrompeM, KotelianskyV, SharpPA, JacksT, AndersonDG (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol32:551–553

[99] ZhenS, HuaL, LiuYH, GaoLC, FuJ, WanDY, DongLH, SongHF, GaoX (2015) Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther22:404–412

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication